List view / Grid view
1 March 2016 | By Victoria White
ProStrakan will make an upfront payment to AstraZeneca of $70 million to acquire the rights to Moventig in the EU, Iceland, Norway, Switzerland and Liechtenstein...
29 February 2016 | By Victoria White
The CHMP positive opinion is based on the results of the head-to-head LUX-Lung 8 trial in patients with SqCC...
29 February 2016 | By F.P.S. Food and Pharma Systems Srl
FPS is pleased to announce the opening of his new R&D and Test Center...
29 February 2016 | By Victoria White
Celgene has announced that that of the Health Service Executive (HSE) of Ireland has recommended two cancer treatments: Imnovid and Abraxane...
29 February 2016 | By Victoria White
DETERMINE, the Phase IIb clinical trial of tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival...
29 February 2016 | By Arwid Ischi, Charles Ischi AG | Kraemer Elektronik
What requirements need to be met by a tablet testing system to guarantee a successful product release? Is it dependable upon the testing system’s quality, speed, technology, flexibility or safety? Kraemer and Ischi explain...
29 February 2016 | By Victoria White
Boehringer Ingelheim's new initiatives are dedicated to raising awareness of IPF, a rare disease that is frequently misdiagnosed and little understood...
29 February 2016 | By Victoria White
LAVOLTA I and II are two identical, randomised, multicentre, placebo-controlled Phase III studies designed to evaluate the efficacy and safety of lebrikizumab...
29 February 2016 | By Victoria White
UCB’s Briviact (brivaracetam) has been authorised in the UK as an add-on treatment for partial onset seizures with or without secondary generalised seizures...
GlaxoSmithKline is improving process efficiency in the production of pharmaceutical powders at its “centre of excellence” plant in Dartford, Kent, by investing in nine new industrial pharmaceutical sieves fitted with the Vibrasonic® Deblinding System from Russell Finex...
26 February 2016 | By Victoria White
The CHMP opinion of the Type-II variation application for Viekirax + Exviera is supported by data from the Phase 3b TURQUOISE-III study...
26 February 2016 | By Victoria White
Ixekizumab is an IgG4 monoclonal antibody that selectively binds with IL-17A cytokine and inhibits its interaction with the IL-17 receptor...
26 February 2016 | By Victoria White
Both indications are supported by Phase 3 studies in which Opdivo demonstrated a survival benefit versus a standard of care...
26 February 2016 | By Victoria White
The LATTE-2 study showed that a regimen of two investigational long-acting, intramuscular (IM) formulations of HIV medicines had comparable antiviral activity to 3-drug oral antiretroviral therapy in HIV-1 infected adults...
26 February 2016 | By Victoria White
Alprolix is a recombinant clotting factor therapy developed for haemophilia B by fusing factor IX to the Fc portion of immunoglobulin G subclass 1...
